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Background: Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation
(ROHHAD) is a rare syndrome with unknown etiology. Metabolic abnormalities are not known to be part of the
syndrome. We present one of the oldest cases reported in the literature, who developed severe metabolic
abnormalities and hepatic disease suggesting that these features may be part of the syndrome.
Case presentation: A 27-year-old woman, diagnosed with ROHHAD syndrome at age 15, who previously developed
diabetes insipidus, growth hormone deficiency, hyperprolactinemia, and hypothyroidism in her first decade of life. This
was followed by insulin resistance, NAFLD, liver fibrosis, and splenomegaly before age 14 years. Her regimen included a
short course of growth hormone, and cyclic estrogen and progesterone. Her metabolic deterioration continued
despite treatment with metformin. Interestingly, she had a favorable response to liraglutide therapy despite having a
centrally mediated cause for her obesity. At age 26, a 1.6 cm lesion was found incidentally in her liver. Liver biopsy
showed hepatocellular carcinoma which was successfully treated with radiofrequency ablation.
Conclusion: Metabolic abnormalities, Insulin resistance and fatty liver disease are potentially part of the ROHHAD
syndrome that may develop over time. GLP1 agonists were reasonably effective to treat insulin resistance and
hyperphagia. Patients with ROHHAD may benefit from close follow up in regards to liver disease.
Keywords: ROHHAD, Insulin resistance, GLP-1 agonists, Obesity, Atypical diabetes
Rapid-onset obesity with hypothalamic dysfunction,
hypoventilation, and autonomic dysregulation (ROHHAD)
is a rare syndrome characterized by hyperphagia and rapid-
onset weight gain that starts in early childhood. The rapid
weight gain is followed by hypothalamic manifestations
with neuroendocrine deficiencies, hypoventilatory breathing
abnormalities, and autonomic dysregulation [1]. A genetic
basis for ROHHAD has not been established, which differ-
entiates it from central hypoventilation syndrome caused
by mutations in the PHOX2B gene [2]. Natural history
information about this rare syndrome is sparse, as the re-
ported mortality rates are high at 50 to 60% [3] within a
short period of time after diagnosis, usually due to
hypoventilation, cardiopulmonary failure or both [4–6].
We have followed an unusual case of ROHHAD
syndrome for two decades, currently age 27 years, and is
believed to be one of the oldest patients with ROHHAD
syndrome. Over time, she developed novel clinical fea-
tures not previously associated with ROHHAD, such as
severe insulin resistance and diabetes mellitus, severe
hypertriglyceridemia, progressive fatty liver disease, and
more recently clinical cirrhosis and hepatocellular car-
cinoma. The clinical management of the hyperglycemia
has been challenging due to the severe insulin resistance
and labile sodium and fluid balance.
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This is a report of a patient who was followed at the
Michigan Medicine Pediatric Endocrinology Clinic until
age 18 years. She was also evaluated at the Lurie
Children’s Hospital Autonomic Dysfunction Program at
the Lurie Children’s Hospital of Chicago at age 16 years.
Subsequently, endocrine care was transitioned to the
Metabolism, Endocrinology and Diabetes Clinic Atypical
Diabetes Program at Michigan Medicine. She was also
followed by the Medical Genetics specialty clinic at Mott
Children’s Hospital of Michigan Medicine during this
time.
The patient gave consent to share her case presenta-
tion in the medical literature and provided her pictures.
Laboratory testing was performed using standard proce-
dures at the clinical pathology laboratory of the Mich-
igan Medicine. PHOX2B gene testing was performed at
the University of Chicago Genetics Laboratory and
whole exome sequencing of the patient and her parents
were performed by GeneDx (Gaithersburg, Maryland)
using samples drawn in February 2017.
Hormonal measurements were performed using the
standard procedures available in the clinical laboratory
at Michigan Medicine manual available at the University
of Michigan Department of Pathology [7] and were re-
ported in the medical record. All the testing that is being
reported here was accomplished during routine clinical
care and no tests done for research purposes are being
reported.
Literature review
A Pubmed search conducted using the terms ROHHAD,
ROHHADNET and the syndrome full name, retrieved
50 articles. These were reviewed and categorized in Add-
itional file 1: Table S2 and further summarized after the
case presentation. Prior to the literature search, we
sought to investigate the age of onset, the life span,
current ages of surviving cases and the frequency of
metabolic (glucose intolerance, insulin resistance or
presence of diabetes) as well as liver related complica-
tions from the reported cases.
Case presentation
A previously healthy, normally developing girl without
familial obesity was evaluated at age 4 years for a sudden
weight gain of 15 pounds in less than 1 year (25th to
95th percentile for weight) and decreased linear growth
(25th to 10th percentile for height; Fig. 1b). She dis-
played no features of lipodystrophy. The medical history
of the patient revealed that she was born to non-
consanguineous healthy parents with a birth weight of 4
pounds 13 oz (2.14 Kg) by c-section at 37 weeks (3
weeks preterm) due to pre-eclampsia. Her growth in the
first year of life included a height at the 75th percentile
and weight at the 25th percentile. She never had any
concerns about developmental delays or cognitive
impairment. However, her parents noted fear and anx-
iety about routine daily activities, entering crowded
spaces as well as decision making, starting around age 4
years. Ophthalmic exam did not show any vision abnor-
malities other than myopia and astigmatism. Given her
mother’s history of hearing impairment, hearing test was
done but did not show any abnormality.
During the initial evaluation, her sodium was 156
mEq/L with undetectable antidiuretic hormone (ADH),
consistent with diabetes insipidus and disrupted thirst
regulation. She was also found to have central
hypothyroidism, elevated prolactin, and growth hormone
deficiency (Table 1). Her baseline cortisol levels were
normal to high with normal ACTH. A hypothalamic
tumor was suspected, but brain MRI was normal (Fig.
1c). Due to the rapid weight gain, she was also worked
up for Cushing’s syndrome, however, abdominal CT re-
vealed no adrenal masses and overnight dexamethasone
suppression test was normal.
She was originally started on subcutaneous DDAVP, and
then transitioned to intranasal spray. She was very closely
monitored with weekly blood draws, tight fluid instructions
and close weight tracking. Despite this tight monitoring,
she still required hospitalizations for hypernatremia at the
time of infections. Given these difficulties, she never tried
oral DDAVP. She was simultaneously treated with levothyr-
oxine replacement.
After age 10, she was diagnosed with nonalcoholic
fatty liver disease (NAFLD) with evidence of progressive
fibrosis over time, resulting in hypersplenism and pan-
cytopenia. Her liver function tests (LFTs) were noted to
be elevated starting at age 10. At age 11, she underwent
a liver US showing the presence of increased fat as well
as splenomegaly. During the same period, she was noted
to have autonomic dysfunction, abnormal thermoregula-
tion, and profuse sweating.
She was treated with growth hormone from age 10 to
age 14 years to assist with linear growth and it was dis-
continued due to increased swelling and weight gain. At
age 10, she was diagnosed with sleep apnea and insulin
resistance. She was started on metformin, but developed
clinical diabetes by age 14. She did not achieve spontan-
eous menarche despite the development of oily skin and
acne and was started on female hormone replacement
with cyclic estrogen and progesterone therapy at the age
of 14.
At age 15, she developed respiratory failure and shock
from an upper respiratory tract infection, requiring intub-
ation, oscillator, and vasopressors. She was able to recover
after a prolonged hospitalization. Shortly after at age 16,
she underwent a thorough evaluation at the Lurie
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Children’s Hospital that documented her autonomic dys-
function and hypoventilation (Additional file 1: Table S1).
Management with overnight ventilator, oxygen supplemen-
tation and oscillator use were recommended. Home con-
tinuous overnight monitoring for oxygen saturation and
heart rate were also initiated. At that time, she underwent
PHOX2B gene testing due to the presence of autonomic
dysfunction and this testing was negative.
Between the ages of 18–23, she was transitioned to





Fig. 1 a Photograph of the patient at age 4 (left) compared to 26 (right). b Coronal view of brain MRI with no abnormality detected c Growth
charts constructed with standard data obtained from CDC [20]. Stature (top), and weight (middle) display a drop in linear growth and significant
weight gain at 4 years of age; increased linear growth upon initiation of growth hormone at age 7 with a plateau following discontinuation at
age 14. BMI (bottom) has been in the obese range since age 4. d 10-day glucose tracing by insulin pump shows improvement in blood glucose
after 8–12 h of starting GLP-1 agonist, liraglutide, on May 16
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noted to become more challenging. She was started on
insulin, with insulin requirement increasing to > 310
international units (IU) while her HbA1c increased to
numbers above 9%. Poor diabetes control made manage-
ment of sodium balance very difficult due to polyuria
and absence of thirst. She developed severe acanthosis
nigricans and lymphedema. Her weight increased to
BMI over 40 kg/m2. Over time, she was started on U500
insulin. She also developed hypertriglyceridemia at this
time with the highest value at 1062mg/dL. Of note,
given the hypertriglyceridemia, low adiponectin levels
and the lack of a commercial test, she was never tested
for presence of the insulin receptor auto-antibody.
She was started on liraglutide 0.6 mg daily with the
hope of improving control and sparing insulin to im-
prove acanthosis nigricans, hyperandrogenism, weight
and fatty liver. Her insulin requirements dropped pre-
cipitously to less than 30% of baseline doses within 8 to
12 h of initiation (Fig. 1d). She was managed with
liraglutide 1.2 mg daily on and off for about 2 years. Ini-
tiation of liraglutide did not cause worsening of her dia-
betes insipidus, hypernatremia, or pancytopenia. She did,
however, experience worsened diarrhea due to the use of
liraglutide leading to treatment interruption. Her
acanthosis nigricans, facial acne and coarsening of facial
features improved due to dose reduction in insulin.
With increased weight gain, swelling, worsening
acanthosis nigricans, a weight reduction diet was
attempted with meal replacement and caloric restriction.
She lost 15 lbs. with this attempt. At the age of 26, she
was noted to have a 1.6 cm Barcelona Clinic Liver
Cancer (BCLC) Stage 0 (T1N0M0 Stage 1) liver lesion
on routine semi-annual liver surveillance because of the
presence of clinical cirrhosis and hypersplenism. The bi-
opsy of the lesion favored the diagnosis of a well differ-
entiated hepatocellular carcinoma (Fig. 2). A
radiofrequency ablation procedure for this was success-
fully completed on 8/30/2018.
In addition, other comorbidities that developed over
the years include cholelithiasis, chronic kidney disease
with nephrotic range proteinuria (no biopsy performed
to date to determine the underlying pathological mecha-
nisms but being contemplated), hypertension, anemia
and thrombocytopenia, splenomegaly, irritable bowel
syndrome, vitamin D deficiency, and mild tricuspid
regurgitation.
Results of literature review
The supplemental file summarizes all cases documented
in the literature. As shown, most cases were quite young
at the time of death or last encounter before the report.
Table 2 summarizes basic clinical characteristics of the
cases and the presence of the features related to insulin
resistance. Overall, there were 117 cases reported. Insu-
lin resistance were documented in only 5 patients and
none of them were older than teenage years. Fatty liver
disease or nonalcoholic steatohepatitis has not been re-
ported previously. Definitive deaths of only 8 patients
were documented in the papers even though many of
the reviews on this disease entity report a high incidence
of mortality before teenage years. Cause of death was
predominantly cardiopulmonary, but infections were
also reported to lead to death. Of note and not included
on the table, premature birth and low birth weight are
not typical features of ROHHAD.
Discussion
Our patient is one of the oldest described with ROH-
HAD who has developed severe insulin resistance while
under observation. This case expands the spectrum of
clinical findings in ROHHAD, to include severe insulin
resistance progressing to diabetes mellitus with compli-
cations, progressive NAFLD with hypersplenism, and
cirrhosis as well as hepatocellular carcinoma.
ROHHAD syndrome is a relatively novel disease. It
was first described by Fishman et al. in 1965 [8], but the
syndrome acquired the name in 2007 by Ize-Ludlow et
al. when the diagnostic criteria were described [9]. To
date, more than 100 cases (n = 117) based on our review)
have been reported in the literature [5]. Recently Lee et
al. reported a systematic review of the reported cases in-
dependent of our efforts, but this review did not focus
on insulin resistance, dyslipidemia or fatty liver disease.
In fact, the summary tables found in that review do not
comment specifically on any of these novel features [10].
The syndrome is quite distinctive from Prader-Willi and
other complex syndromes of obesity due to its sudden
Table 1 Childhood labs
Value Reference Range
IGF-1, ng/mL 41 70–288
GH stimulation testing GH undetectable at baseline and all-time
points after stimulation with arginine and
insulin-induced hypoglycemia to 49mg/dL
Prolactin, ng/mL 50 1–17
ADH, pg/mL 1.7 < 1.7
Serum Na, meq/L 156 132–145
Morning cortisol, mcg/dL 12.7 < 20
TSH, mU/L 0.87 0.3–5.5
Free T4, ng/dL 0.99 0.73–1.79
Estradiol at age 12, pg/mL 8.0 < 10 prepubertal
FSH, mIU/L 0.2 3–26
LH, mIU/L 0.5 2–105
Abbreviations: IGF-1, insulin like growth factor-1; GH, growth hormone; TSH,
thyroid stimulating hormone; LH, luteinizing hormone. A leptin level at age 22
was measured at 99 ng/ml and an adiponectin level was 3 mcg/ml which
was low
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onset acquired nature, absence of symptoms at birth,
predominance of autonomic features, and respiratory ab-
normalities as well as diabetes insipidus and
hyperprolactinemia.
The condition is characterized by high morbidity and
mortality rates [3, 11]. Forty per cent of patients were
noted to develop neural crest tumors (ganglioneuroma,
ganglioneuroblastoma); it was suggested that the acro-
nym ROHHAD could be extended to ROHHADNET
(ROHHAD-neuroendocrine tumors) [11]. Previously
recognized features of the syndrome include obesity,
alveolar hypoventilation, autonomic dysregulation, sym-
pathetic nervous system tumors. While at this point, we
cannot rule out the existence of two separate disorders
in our patient leading to a blended phenotype, we sug-
gest that severe insulin resistance and progressive fatty
liver disease may be features to the syndrome. We also
want to draw attention to this case as a cause for the de-
velopment of atypical diabetes. Evaluation of patients
with ROHHAD shoudl include evaluation for these po-
tential complications and with time, we may learn the
frequency of these features in ROHHAD.
The etiology of the syndrome is not known. Molecular
diagnostic studies including PHOX2B gene testing and
whole exome interrogation in conjunction with her par-
ents did not reveal any causative genetic alterations in
our patient including monogenic or syndromic obesity
or known syndromes of insulin resistance (including the
insulin receptor). In 2011, Patwari et al. reported mono-
zygotic twins, one of whom had ROHHAD syndrome
while the other twin did not, [12] suggesting that the
disease may not develop due to genomic changes. Even





Fig. 2 a MRI abdomen showing hepatocellular carcinoma in the left lobe (BCLC stage A). b The liver mass biopsy showed a small amount of
fibrotic background liver. The main lesion was a well-differentiated hepatocellular neoplasm composed of sheets of lesional hepatocytes and
absence of normal portal structures. c This higher magnification of the hepatocellular neoplasm shows an unpaired artery (*) and surrounding
well-differentiated neoplastic hepatocytes. d Trichrome stain highlights cirrhotic background
Table 2 Case summary
Result
Diagnosis age, years (n = 23) 5.6 (3.1)
Age at last encounter, years (n = 25) 8.9 (4.7)
Number of cases reported 117









Disconnection from ventilator support 1
Data are presented as Mean (SD) or count out of 117 cases.
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postulated that ROHHAD may be an immune-mediated
central nervous system (CNS) disorder [6, 13–15] or
epigenetic factors may have a role in the pathogenesis
of the syndrome [12]. In this regard, it was interesting
that our patient did not demonstrate any laboratory
features suggesting other autoimmune diseases at any
point. Periodically performed imaging studies did not
reveal any neural crest tumors to date either.
Other than the well described pituitary hormonal defi-
ciencies, diabetes insipidus and hyperprolactinemia,
other hormonal features of this syndrome are not de-
scribed. Our patient had a high circulating leptin level.
We are not sure if this can be generalized to other ROH-
HAD patients. We did not study the incretin secretion
or other circulating mediators of appetite control or en-
ergy balance in our patient and are not aware of these
investigations in other patients.
Our case presented several challenges and lessons to
us that are worth sharing. She was prepubertal when she
presented with the earliest signs of insulin resistance.
She was treated with metformin almost immediately, but
this did not prevent the development of severe acantho-
sis nigricans, oily skin, hirsutism and coarsening of fea-
tures, despite the presence of central hypogonadism,
suggesting that insulin resistance alone can drive these
aspects of clinical presentation without any central
stimulation of the pituitary. She was treated with cyclic
estrogen and progesterone replacement for bone health.
Our patient was also treated with growth hormone for
several years to assist with linear growth, but this was
kept short due to worsening weight gain and swelling.
Management of her case from childhood through early
adulthood remained quite complicated and she required
frequent lab monitoring and clinical visits. Both her par-
ents and herself remained very vigilant about her care.
Long term survivors with this syndrome need to be
closely monitored and care transitions from pediatric to
adult endocrinology should be undertaken in a planned
manner.
Insulin resistance and adult growth hormone defi-
ciency are associated with non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatosis
(NASH); the latter can progress to liver cirrhosis and he-
patocellular carcinoma in some cases [16]. High doses of
insulin, growth hormone, and even estrogen may have
also contributed to the development of hepatocellular
cancer [17]. In addition, prolactin receptors are some-
times expressed in hepatocellular cancers [18] and our
patient has had mild, but untreated hyperprolactinemia
since the onset of her condition. Our patient’s hyperpro-
lactinemia was never adequately addressed; dopamine
agonists were never initiated due to the presence of
autonomic dysfunction, and fear of worsening orthosta-
sis. We recommend screening for hepatic lesions using
abdominal ultrasound in other patients presenting with
the clinical features of NAFLD in the setting of ROH-
HAD as they grow older, particularly if they have signs
of advanced hepatic fibrosis or cirrhosis. In addition,
presence of clinical diabetes and insulin resistance
should also be screened in addition to various endocrine
manifestations.
The immediate improvement in glycemic control fol-
lowing liraglutide initiation indicates that the insulin re-
sistance seen in this patient can be partially overcome
with glucagon-like peptide-1 (GLP-1) agonism and adds
to the growing evidence that GLP-1 receptor agonists
may exert their metabolic actions via neural circuitry
located outside of the hypothalamus, or via peripheral
mechanisms [19]. Treatment experience in a larger
number of patients is needed to validate these early
observations.
Finally, our patient’s sodium and fluid balance man-
agement were markedly tenuous on account of poorly
controlled diabetes, presence of diabetes insipidus and
absence of thirst regulation. The patient required weekly
sodium monitoring and constant adjustment of her fluid
intake recommendation and her DDAVP dose. Inter-
current illnesses (such as upper respiratory tract, urinary
tract infections, or cellulitis episodes) and natural
temperature fluctuations impacted her sodium levels.
Our patient had multiple hospitalizations for dehydra-
tion and hypernatremia despite being compliant with
instructions and carrying out frequent laboratory testing.
Ideal glucose control (also a challenging goal for this pa-
tient) was essential to maintain her sodium balance
closer to the normal range.
Conclusion
ROHHAD is an interesting syndrome presenting with a
characteristic cluster of abnormalities. There appears to be
heterogeneity among patients diagnosed with ROHHAD
and careful clinical characterization is required to more
precisely define this disease entity. Our case expands on the
clinical features of this syndrome to include severe and pro-
gressive insulin resistance and fatty liver disease. It should
be noted that the fatty liver disease in this condition can be
aggressive and result in development of cirrhosis that can
be complicated by hepatocellular carcinoma.
Additional file
Additional file 1: Table S1. Autonomic testing available on subject.
Table S2 Summary data abstracted from reported cases and respective
references. (DOCX 79 kb)
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